Home › Research › Risk factors
Linking Metabolic Syndrome to Neurodegeneration Mechanisms and Potential Treatments
Amina Džidić-Krivić, Almir Fajkić, Esma Karahmet Farhat, Lana Lekić, Amira Ejubović, Samra Kadić Vukas, Malik Ejubović, Orhan Lepara et al.. Molecular neurobiology, 2025-04-24
Topic: Gut, metabolism and diet
Plain-language summary
The global rise in both metabolic syndrome (MetS) and neurodegenerative diseases (NDs), particularly dementia and Alzheimer's disease (AD) poses a growing health and socioeconomic burden. MetS affects approximately 25% of the global adult population and is associated with insulin resistance, hypertension, dyslipidemia, and obesity, factors increasingly linked to cognitive impairment and brain atrophy. This review explores the shared pathophysiological mechanisms between MetS and NDs, including neuroinflammation, oxidative stress, insulin resistance in the brain, blood-brain barrier (BBB) dysfunction, mitochondrial damage, gut microbiota dysbiosis, and alterations in the renin-angiotensin system. In terms of substance, MetS patients are four times more likely to develop dementia, with increased markers such as CRP and IL-6 present in the patient populations. The review suggests the role of astrocytic insulin signalling, adipokines, and toll-like receptors as key molecular links. Interventions such as caloric restriction, hydroxytyrosol (HT), and intranasal insulin have shown promising outcomes at preclinical and early clinical stages. Antidiabetic drugs like metformin, liraglutide, and GLP-1 receptor agonists have the potential to modulate neuroinflammation and improve cognition. Angiotensin receptor blockers like losartan and candesartan also exhibit neuroprotection via RAS pathway modulation. The review emphasizes the need for longitudinal studies and clinical trials to confirm these therapeutic agents and develop effective and cost-friendly interventions for the prevention and management of neurodegeneration in patients with metabolic syndrome.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Džidić-Krivić, A., Fajkić, A., Farhat, E. K., Lekić, L., Ejubović, A., Vukas, S. K., et al. (2025). Linking Metabolic Syndrome to Neurodegeneration Mechanisms and Potential Treatments. Molecular neurobiology. https://doi.org/10.1007/s12035-025-04947-w
Vancouver
Džidić-Krivić A, Fajkić A, Farhat EK, Lekić L, Ejubović A, Vukas SK, et al. Linking Metabolic Syndrome to Neurodegeneration Mechanisms and Potential Treatments. Molecular neurobiology. 2025. doi:10.1007/s12035-025-04947-w. PMID: 40272771.
BibTeX
@article{dzidickrivic2025-40272771,
author = {Džidić-Krivić, Amina and Fajkić, Almir and Farhat, Esma Karahmet and Lekić, Lana and Ejubović, Amira and Vukas, Samra Kadić and Ejubović, Malik and Lepara, Orhan and others},
title = {{Linking Metabolic Syndrome to Neurodegeneration Mechanisms and Potential Treatments}},
journal = {Molecular neurobiology},
year = {2025},
doi = {10.1007/s12035-025-04947-w},
pmid = {40272771},
url = {https://doi.org/10.1007/s12035-025-04947-w}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- MetS affects approximately 25% of the global adult population and is associated with insulin resistance, hypertension, dyslipidemia, and obesity, factors increasingly linked to cognitive impairment and brain atrophy.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 59/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 33 of the 56 points we could judge it on, which is 59 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular neurobiology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40272771) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 33 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 33 of the 56 points we could judge it on is 59 out of 100. |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Risk factors from nearby years
Also tagged “peptide-1”
285 studies in the library carry the topic tag “peptide-1”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 285 tagged studies.